Trial completion date • Trial primary completion date • Combination therapy
|
BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase)
|
TP53 mutation • BRAF V600E • EGFR mutation • BRAF V600 • EGFR T790M • TP53 wild-type • ALK rearrangement
|
brigimadlin (BI 907828) • ezabenlimab (BI 754091) • miptenalimab (BI 754111)